Day

November 21, 2018
BMC via IV Therapy

Considerations On the Regulatory Status of IV Administration of BMC: A Useful Shot in the Arm? Part Three

Over the previous couple of posts, I have been reviewing the love/hate relationship the FDA seems to have with therapy provided by an IV route. They issued a blanket determination in the MM/HU Guidance that IV therapies of HCT/Ps would be considered risky and therefore physicians offering IV therapies of HCT/Ps would be more rapidly...
Read More